JP2023531990A5 - - Google Patents
Info
- Publication number
- JP2023531990A5 JP2023531990A5 JP2022579797A JP2022579797A JP2023531990A5 JP 2023531990 A5 JP2023531990 A5 JP 2023531990A5 JP 2022579797 A JP2022579797 A JP 2022579797A JP 2022579797 A JP2022579797 A JP 2022579797A JP 2023531990 A5 JP2023531990 A5 JP 2023531990A5
- Authority
- JP
- Japan
- Prior art keywords
- nonspecific binding
- binding
- transfectant
- pseudo
- observed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062705434P | 2020-06-26 | 2020-06-26 | |
| US62/705,434 | 2020-06-26 | ||
| US202062705608P | 2020-07-07 | 2020-07-07 | |
| US62/705,608 | 2020-07-07 | ||
| EP20205426.8 | 2020-11-03 | ||
| EP20205426 | 2020-11-03 | ||
| PCT/EP2021/067574 WO2021260206A2 (en) | 2020-06-26 | 2021-06-25 | Chemokine receptor antibodies binding sulfated trd motifs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023531990A JP2023531990A (ja) | 2023-07-26 |
| JP2023531990A5 true JP2023531990A5 (enExample) | 2024-07-02 |
Family
ID=76553783
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022579796A Pending JP2023531989A (ja) | 2020-06-26 | 2021-06-25 | Ｃｃｒ８抗体及びその使用 |
| JP2022579794A Pending JP2023531988A (ja) | 2020-06-26 | 2021-06-25 | 治療用途のためのｃｃｒ８抗体 |
| JP2022579795A Pending JP2023531705A (ja) | 2020-06-26 | 2021-06-25 | 抗ｃｃｒ８抗体療法：バイオマーカー及び併用療法 |
| JP2022579798A Pending JP2023531991A (ja) | 2020-06-26 | 2021-06-25 | ケモカイン受容体抗体生成のための硫酸化ペプチド |
| JP2022579797A Pending JP2023531990A (ja) | 2020-06-26 | 2021-06-25 | 硫酸化ｔｒｄモチーフに結合するケモカイン受容体抗体 |
Family Applications Before (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022579796A Pending JP2023531989A (ja) | 2020-06-26 | 2021-06-25 | Ｃｃｒ８抗体及びその使用 |
| JP2022579794A Pending JP2023531988A (ja) | 2020-06-26 | 2021-06-25 | 治療用途のためのｃｃｒ８抗体 |
| JP2022579795A Pending JP2023531705A (ja) | 2020-06-26 | 2021-06-25 | 抗ｃｃｒ８抗体療法：バイオマーカー及び併用療法 |
| JP2022579798A Pending JP2023531991A (ja) | 2020-06-26 | 2021-06-25 | ケモカイン受容体抗体生成のための硫酸化ペプチド |
Country Status (15)
| Country | Link |
|---|---|
| US (5) | US20230250178A1 (enExample) |
| EP (5) | EP4172202A2 (enExample) |
| JP (5) | JP2023531989A (enExample) |
| KR (2) | KR20230028453A (enExample) |
| CN (6) | CN116096749A (enExample) |
| AU (2) | AU2021295721A1 (enExample) |
| BR (1) | BR112022026121A2 (enExample) |
| CA (3) | CA3188142A1 (enExample) |
| CL (1) | CL2022003747A1 (enExample) |
| IL (2) | IL298910A (enExample) |
| JO (1) | JOP20220352A1 (enExample) |
| MX (2) | MX2022015968A (enExample) |
| PE (1) | PE20231200A1 (enExample) |
| TW (1) | TW202216771A (enExample) |
| WO (5) | WO2021260206A2 (enExample) |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117964757A (zh) | 2020-02-14 | 2024-05-03 | 吉利德科学公司 | 与ccr8结合的抗体和融合蛋白及其用途 |
| CN115768792A (zh) * | 2020-03-23 | 2023-03-07 | 百时美施贵宝公司 | 抗ccr8抗体用于治疗癌症 |
| EP4173636A4 (en) * | 2020-06-30 | 2024-08-28 | Shionogi & Co., Ltd | Combined use of anti-ccr8 antibody and chemotherapeutic agent |
| CA3198647A1 (en) | 2020-10-16 | 2022-04-21 | LaNova Medicines Limited | Anti-ccr8 monoclonal antibodies and uses thereof |
| JPWO2022211046A1 (enExample) | 2021-03-31 | 2022-10-06 | ||
| IL308808A (en) | 2021-06-04 | 2024-01-01 | Amgen Inc | Antibodies against CCR8 and their uses |
| FI4214240T3 (fi) | 2021-07-27 | 2024-11-14 | Abbvie Inc | Ccr8-vasta-aineita |
| US20250019451A1 (en) * | 2021-08-20 | 2025-01-16 | Hifibio, Inc. | Anti-ccr8 antibodies and uses thereof |
| AU2022375782B2 (en) | 2021-10-28 | 2026-02-26 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
| AU2022376954B2 (en) | 2021-10-29 | 2026-04-23 | Gilead Sciences, Inc. | Cd73 compounds |
| CN116023468A (zh) * | 2021-11-05 | 2023-04-28 | 山东省分析测试中心 | 一种ccr6单克隆抗体及其在免疫及抗肿瘤中的应用 |
| JP2024541680A (ja) * | 2021-12-02 | 2024-11-08 | ザイ ラボ （シャンハイ） カンパニー、リミテッド． | Ｃｃｒ８抗原結合ユニット及びその使用 |
| CA3237577A1 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| AU2022419982B2 (en) | 2021-12-22 | 2026-04-16 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| EP4493554A1 (en) | 2022-03-17 | 2025-01-22 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| CR20240451A (es) | 2022-04-21 | 2024-12-04 | Gilead Sciences Inc | Compuestos de modulación de kras g12d |
| US20260028409A1 (en) | 2022-05-24 | 2026-01-29 | Bristol-Myers Squibb Company | Antibodies that bind to human ccr8 |
| WO2023240135A2 (en) | 2022-06-07 | 2023-12-14 | Actinium Pharmaceuticals, Inc. | Bifunctional chelators and conjugates |
| JP2025520412A (ja) * | 2022-06-14 | 2025-07-03 | パーデュー・リサーチ・ファウンデーション | 薬物ナノ粒子がロードされたｃａｒ発現多能性幹細胞由来好中球およびその使用 |
| PE20250758A1 (es) | 2022-07-01 | 2025-03-13 | Gilead Sciences Inc | Compuestos de cd73 |
| WO2024026400A2 (en) * | 2022-07-27 | 2024-02-01 | Varian Medical Systems, Inc. | Therapeutic combinations of titr effectors with radiation therapy |
| JP2025530159A (ja) * | 2022-09-09 | 2025-09-11 | バイエル・アクチエンゲゼルシヤフト | Ｃｃｒ８抗体の医学的使用および投与スケジュール |
| EP4590705A1 (en) | 2022-09-21 | 2025-07-30 | Domain Therapeutics | Anti-ccr8 monoclonal antibodies and their therapeutic use |
| WO2024062076A1 (en) | 2022-09-21 | 2024-03-28 | Domain Therapeutics | Anti-ccr8 monoclonal antibodies and their therapeutic use |
| WO2024062072A2 (en) | 2022-09-21 | 2024-03-28 | Domain Therapeutics | Anti-ccr8 monoclonal antibodies and their therapeutic use |
| WO2024059909A1 (en) * | 2022-09-21 | 2024-03-28 | Monash University | Anti-ccr8 antibodies |
| AU2023356218A1 (en) * | 2022-10-07 | 2025-04-24 | Genentech, Inc. | Methods of treating cancer with anti-c-c motif chemokine receptor 8 (ccr8) antibodies |
| KR20250091252A (ko) * | 2022-10-28 | 2025-06-20 | 바이오사이토젠 파마슈티컬스 (베이징) 컴퍼니 리미티드 | 항-ccr8 항체 및 이의 용도 |
| WO2024097741A1 (en) * | 2022-11-04 | 2024-05-10 | Gilead Sciences, Inc. | Anticancer therapies using anti-ccr8 antibody, chemo and immunotherapy combinations |
| KR20250130296A (ko) * | 2022-11-22 | 2025-09-01 | 상하이 홍쳉 바이오파머수티컬 코., 엘티디. | 항-ccr8 항체 및 이의 용도 |
| CN120225509A (zh) | 2022-12-22 | 2025-06-27 | 吉利德科学公司 | Prmt5抑制剂及其用途 |
| AR131785A1 (es) * | 2023-02-06 | 2025-04-30 | Bayer Ag | Combinaciones de inhibidores de dgk (diacilglicerol quinasa) |
| AU2024252725A1 (en) | 2023-04-11 | 2025-11-06 | Gilead Sciences, Inc. | Kras modulating compounds |
| PE20260121A1 (es) | 2023-04-21 | 2026-01-16 | Gilead Sciences Inc | Inhibidores de prmt5 y usos de los mismos |
| TW202511293A (zh) * | 2023-05-23 | 2025-03-16 | 中國大陸商再鼎醫藥（上海）有限公司 | 包含抗ｃｃｒ８抗體的製劑及其用途 |
| WO2024248037A1 (ja) | 2023-05-30 | 2024-12-05 | 塩野義製薬株式会社 | Ｃｃｒ８を抗原として認識する二重特異性抗体 |
| KR20260026018A (ko) * | 2023-06-16 | 2026-02-25 | 제노 바이오파마 컴퍼니 리미티드 | 항-ccr8 항체 및 항-ccr8/ctla4 이중특이성 항체 |
| AU2024306338A1 (en) | 2023-06-30 | 2026-01-08 | Gilead Sciences, Inc. | Kras modulating compounds |
| WO2025011439A1 (zh) * | 2023-07-07 | 2025-01-16 | 齐鲁制药有限公司 | 一种抗人ccr8的单克隆抗体药物制剂及其用途 |
| WO2025024811A1 (en) | 2023-07-26 | 2025-01-30 | Gilead Sciences, Inc. | Parp7 inhibitors |
| KR20260046403A (ko) | 2023-07-26 | 2026-04-07 | 길리애드 사이언시즈, 인코포레이티드 | Parp7 저해제 |
| CN117285627B (zh) * | 2023-09-06 | 2024-06-14 | 百济神州(上海)生物科技有限公司 | 抗ccr8抗体及其用途 |
| US20250101042A1 (en) | 2023-09-08 | 2025-03-27 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| AU2024337913A1 (en) | 2023-09-08 | 2026-03-26 | Gilead Sciences, Inc. | Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds |
| WO2025058000A1 (ja) | 2023-09-13 | 2025-03-20 | 東レ株式会社 | 癌の治療、予防及び／又は診断用医薬組成物 |
| EP4590714A1 (en) | 2023-09-21 | 2025-07-30 | Domain Therapeutics | Anti-ccr8 monoclonal antibodies and their therapeutic use |
| WO2025061994A1 (en) | 2023-09-21 | 2025-03-27 | Domain Therapeutics | Anti-ccr8 monoclonal antibodies and their therapeutic use |
| AU2024354737A1 (en) | 2023-10-06 | 2026-04-16 | Amgen Inc. | Combination therapy for cancer treatment |
| US20250154172A1 (en) | 2023-11-03 | 2025-05-15 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| TW202540200A (zh) | 2023-12-01 | 2025-10-16 | 美商基利科學股份有限公司 | 抗ｆａｐ－ｌｉｇｈｔ融合蛋白及其用途 |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025145207A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg-depleting agent |
| WO2025146065A1 (en) * | 2024-01-05 | 2025-07-10 | LaNova Medicines Limited | Clinical regimens of anti-ccr8 antibodies |
| WO2025186043A1 (en) | 2024-03-06 | 2025-09-12 | Bayer Aktiengesellschaft | Pharmaceutical formulation for anti-ccr8 antibodies |
| CN118608914B (zh) * | 2024-04-25 | 2024-11-29 | 中山大学附属第一医院 | 一种病理图像上三级淋巴结构的识别方法、装置、计算机设备及可读存储介质 |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025245003A1 (en) | 2024-05-21 | 2025-11-27 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| US20260056209A1 (en) | 2024-06-14 | 2026-02-26 | Gilead Sciences, Inc. | Anti-ccr8 antibodies and uses thereof |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026039365A1 (en) | 2024-08-12 | 2026-02-19 | Gilead Sciences, Inc. | Kras modulating compounds |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026089992A1 (en) | 2024-10-21 | 2026-04-30 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| ES2284161T3 (es) | 1990-01-12 | 2007-11-01 | Amgen Fremont Inc. | Generacion de anticuerpos xenogenicos. |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| US6329510B1 (en) * | 1999-01-29 | 2001-12-11 | Millennium Pharmaceuticals, Inc. | Anti-CCR1 antibodies and methods of use therefor |
| JP2003530325A (ja) * | 2000-03-31 | 2003-10-14 | イーペーエフ ファルマシューティカルス ゲゼルシャフト ミット ベシュレンクテル ハフツング | 好ましくは特異的ケモカインレセプター分析、及びケモカインレセプター／リガンド相互作用の助けによる、腫瘍及び炎症細胞の細胞表面プロテオームの調査、並びに腫瘍疾患及び炎症性疾患の治療のための診断薬及び薬剤 |
| WO2003096020A2 (en) | 2002-05-13 | 2003-11-20 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with chemokine receptor 8 (ccr8) |
| AU2003300776A1 (en) * | 2002-09-09 | 2004-05-25 | Omeros Corporation | G protein coupled receptors and uses thereof |
| US20080260744A1 (en) * | 2002-09-09 | 2008-10-23 | Omeros Corporation | G protein coupled receptors and uses thereof |
| JP2007528711A (ja) * | 2003-06-30 | 2007-10-18 | バイオ−テクノロジー・ジェネラル（イスラエル）リミテッド | 抗体及びその使用 |
| US20050266009A1 (en) * | 2003-06-30 | 2005-12-01 | Savient Pharmaceuticals, Inc. | Antibodies and uses thereof |
| US20050069955A1 (en) * | 2003-06-30 | 2005-03-31 | Daniel Plaksin | Antibodies and uses thereof |
| US7435596B2 (en) | 2004-11-04 | 2008-10-14 | St. Jude Children's Research Hospital, Inc. | Modified cell line and method for expansion of NK cell |
| PL2921500T3 (pl) | 2004-07-10 | 2024-02-05 | The Institute For Cancer Research | Genetycznie zmodyfikowane ludzkie linie komórkowe naturalni zabójcy |
| WO2007044756A2 (en) * | 2005-10-11 | 2007-04-19 | Icos Corporation | Monoclonal antibodies recognizing human ccr8 |
| US20070298034A9 (en) * | 2005-12-09 | 2007-12-27 | Angela Widom | Sulfotyrosine specific antibodies and uses therefor |
| CN101720368A (zh) | 2007-03-09 | 2010-06-02 | 中国抗体制药有限公司 | 储备多样性最大化的功能性人化抗体文库之构建及应用 |
| GB0904214D0 (en) * | 2009-03-11 | 2009-04-22 | Ucb Pharma Sa | Biological products |
| UY32560A (es) | 2009-04-29 | 2010-11-30 | Bayer Schering Pharma Ag | Inmunoconjugados de antimesotelina y usos de los mismos |
| BR112012006388B1 (pt) | 2009-09-22 | 2022-01-04 | Probiogen Ag | Método para produzir uma molécula, e, método para produzir uma proteína |
| WO2015148820A1 (en) * | 2014-03-27 | 2015-10-01 | Massachusetts Institute Of Technology | Water-soluble membrane proteins and methods for the preparation and use thereof |
| US10087259B1 (en) | 2014-04-28 | 2018-10-02 | Memorial Sloan Kettering Cancer Center | Depleting tumor-specific tregs |
| DK3149045T3 (da) * | 2014-05-27 | 2023-03-06 | Academia Sinica | Sammensætninger og fremgangsmåder vedrørende universelle glycoformer til forbedret antistofeffekt |
| MA41176A (fr) | 2014-12-17 | 2017-10-24 | Bayer As | Complexes radio-pharmaceutiques |
| AU2016305283B2 (en) * | 2015-08-10 | 2022-05-26 | Pepmab B.V. | Humanized anti-CCR7 receptor antibodies |
| KR102111338B1 (ko) | 2015-10-02 | 2020-05-15 | 제넨테크, 인크. | 피롤로벤조디아제핀 항체 약물 콘쥬게이트 및 이의 사용 방법 |
| EP4092045A1 (en) | 2016-05-16 | 2022-11-23 | Checkmab S.R.L. | Markers selectively deregulated in tumor-infiltrating regulatory t cells |
| CN109475600A (zh) | 2016-06-17 | 2019-03-15 | 瓦里安医疗系统公司 | 免疫调节剂与辐射治疗组合 |
| WO2018112033A1 (en) | 2016-12-13 | 2018-06-21 | President And Fellows Of Harvard College | Methods and compositions for targeting tumor-infiltrating tregs |
| ES2863412T3 (es) * | 2017-03-29 | 2021-10-11 | Shionogi & Co | Composición farmacéutica para el tratamiento del cáncer |
| BR112020010753A2 (pt) * | 2017-12-01 | 2020-11-24 | The Regents Of The University Of California | anticorpos anti-cxcr5 e composições e usos dos mesmos |
| WO2019149637A1 (en) | 2018-01-31 | 2019-08-08 | Bayer Aktiengesellschaft | Antibody drug conjugates (adcs) with nampt inhibitors |
| WO2019157098A1 (en) * | 2018-02-06 | 2019-08-15 | Advaxis, Inc. | Compositions comprising a recombinant listeria strain and an anti-ccr8 antibody and methods of use |
| KR20210033470A (ko) | 2018-06-18 | 2021-03-26 | 바이엘 악티엔게젤샤프트 | 효소에 의해 절단 가능한 링커 및 개선된 활성 프로파일을 갖는, cxcr5에 대해 유도된 결합제-약물 접합체 |
| CN110835374A (zh) * | 2018-08-19 | 2020-02-25 | 普米斯生物技术(苏州)有限公司 | 抗ccr8×ctla-4双特异性抗体及其应用 |
| WO2020102240A1 (en) | 2018-11-13 | 2020-05-22 | Memorial Sloan Kettering Cancer Center | Compositions and methods for adoptive cell therapy for cancer |
| KR102940634B1 (ko) * | 2018-12-27 | 2026-03-17 | 시오노기세이야쿠가부시키가이샤 | 신규 항 ccr8 항체 |
| TWI906906B (zh) | 2020-01-06 | 2025-12-01 | 美商法西尼克斯股份有限公司 | 抗ccr8抗體及其用途 |
| CN117964757A (zh) | 2020-02-14 | 2024-05-03 | 吉利德科学公司 | 与ccr8结合的抗体和融合蛋白及其用途 |
| WO2021178749A2 (en) | 2020-03-05 | 2021-09-10 | Memorial Sloan Kettering Cancer Center | Anti-ccr8 agents |
| CN115768792A (zh) | 2020-03-23 | 2023-03-07 | 百时美施贵宝公司 | 抗ccr8抗体用于治疗癌症 |
| EP4173636A4 (en) | 2020-06-30 | 2024-08-28 | Shionogi & Co., Ltd | Combined use of anti-ccr8 antibody and chemotherapeutic agent |
| WO2022003156A1 (en) | 2020-07-02 | 2022-01-06 | Oncurious Nv | Ccr8 non-blocking binders |
| CN115989223B (zh) | 2020-07-03 | 2024-09-20 | 南京艾美斐生物医药科技有限公司 | 使用CCR8抑制剂靶向Tregs的方法和组合物 |
| WO2022053031A1 (en) | 2020-09-11 | 2022-03-17 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Genetically modified non-human animal with human or chimeric ccr8 |
| CN118852430A (zh) * | 2023-04-28 | 2024-10-29 | 南京诺艾新生物技术有限公司 | 一种抗趋化因子受体8的抗体及其应用 |
-
2021
- 2021-06-24 TW TW110123093A patent/TW202216771A/zh unknown
- 2021-06-25 EP EP21736313.4A patent/EP4172202A2/en active Pending
- 2021-06-25 PE PE2022003003A patent/PE20231200A1/es unknown
- 2021-06-25 EP EP21736311.8A patent/EP4171601A2/en active Pending
- 2021-06-25 JP JP2022579796A patent/JP2023531989A/ja active Pending
- 2021-06-25 CA CA3188142A patent/CA3188142A1/en active Pending
- 2021-06-25 EP EP21736310.0A patent/EP4172201A2/en active Pending
- 2021-06-25 BR BR112022026121A patent/BR112022026121A2/pt unknown
- 2021-06-25 KR KR1020237002373A patent/KR20230028453A/ko active Pending
- 2021-06-25 JP JP2022579794A patent/JP2023531988A/ja active Pending
- 2021-06-25 CN CN202180047298.XA patent/CN116096749A/zh active Pending
- 2021-06-25 MX MX2022015968A patent/MX2022015968A/es unknown
- 2021-06-25 IL IL298910A patent/IL298910A/en unknown
- 2021-06-25 CN CN202180047296.0A patent/CN116096395A/zh active Pending
- 2021-06-25 EP EP21736312.6A patent/EP4171602A2/en active Pending
- 2021-06-25 AU AU2021295721A patent/AU2021295721A1/en active Pending
- 2021-06-25 MX MX2022015954A patent/MX2022015954A/es unknown
- 2021-06-25 WO PCT/EP2021/067574 patent/WO2021260206A2/en not_active Ceased
- 2021-06-25 KR KR1020237002375A patent/KR20230028780A/ko active Pending
- 2021-06-25 JP JP2022579795A patent/JP2023531705A/ja active Pending
- 2021-06-25 WO PCT/EP2021/067504 patent/WO2021152186A2/en not_active Ceased
- 2021-06-25 CN CN202180047293.7A patent/CN116096748A/zh active Pending
- 2021-06-25 CN CN202311684511.5A patent/CN117653725A/zh active Pending
- 2021-06-25 JP JP2022579798A patent/JP2023531991A/ja active Pending
- 2021-06-25 WO PCT/EP2021/067579 patent/WO2021260209A2/en not_active Ceased
- 2021-06-25 CA CA3188146A patent/CA3188146A1/en active Pending
- 2021-06-25 WO PCT/EP2021/067580 patent/WO2021260210A2/en not_active Ceased
- 2021-06-25 CN CN202180047299.4A patent/CN116096750A/zh active Pending
- 2021-06-25 CN CN202180047358.8A patent/CN116234825A/zh active Pending
- 2021-06-25 EP EP21734019.9A patent/EP4172204A2/en active Pending
- 2021-06-25 US US18/003,118 patent/US20230250178A1/en active Pending
- 2021-06-25 IL IL298896A patent/IL298896A/en unknown
- 2021-06-25 US US17/358,841 patent/US11427640B1/en active Active
- 2021-06-25 JP JP2022579797A patent/JP2023531990A/ja active Pending
- 2021-06-25 AU AU2021212327A patent/AU2021212327A1/en active Pending
- 2021-06-25 WO PCT/EP2021/067578 patent/WO2021260208A2/en not_active Ceased
- 2021-06-25 CA CA3188138A patent/CA3188138A1/en active Pending
-
2022
- 2022-04-22 US US17/727,220 patent/US12065497B2/en active Active
- 2022-12-23 CL CL2022003747A patent/CL2022003747A1/es unknown
- 2022-12-27 JO JOJO/P/2022/0352A patent/JOP20220352A1/ar unknown
-
2024
- 2024-05-16 US US18/666,545 patent/US20240400700A1/en active Pending
- 2024-05-16 US US18/666,512 patent/US20240376218A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023531991A5 (enExample) | ||
| JP2023531705A5 (enExample) | ||
| JP2023531989A5 (enExample) | ||
| JP2023531988A5 (enExample) | ||
| NO20161389A1 (no) | Antistoffer som binder til human IGF-IR, hybridomcellelinjer og nukleinsyrer, farmasøytisk blanding omfattende samme, anvendelse av samme for fremstilling av farmasøytisk blanding, fremgangsmåte for fremstilling av farmasøytisk preparat, og anvendelser derav | |
| JP2011525355A5 (enExample) | ||
| JP2012143232A5 (enExample) | ||
| WO2008016854A3 (en) | Methods and compositions related to soluble monoclonal variable lymphocyte receptors of defined antigen specificity | |
| JP2024511319A5 (enExample) | ||
| JP2002524024A5 (enExample) | ||
| MX2023008000A (es) | Conjugados de anticuerpo dirigido a b7-h4 y farmaco, y metodos de uso de los mismos. | |
| CY1118949T1 (el) | Ανθρωπινα αντισωματα που προσδενουν cxcr4 και χρησεις αυτων | |
| NO20090069L (no) | Malrettede forbindelser rettet mot binding til PDGFR-alfa og deres anvendelse | |
| WO2007041171A3 (en) | Method of identifying membrane lg specific antibodies and use thereof for targeting immunoglobulin-producing precursor cells | |
| JP2007051159A5 (enExample) | ||
| JP2004531270A5 (enExample) | ||
| ATE551314T1 (de) | Gasphasensynthese von 2,3,3,3-tetrafluor-1-propen aus 2-chlor-3,3,3-trifluor-1-propen | |
| EP2826791A3 (en) | Humanized anti-C5aR antibodies | |
| IL179427A0 (en) | Antibodies as t cell receptor mimics, methods of production and uses thereof | |
| JP2014509837A5 (enExample) | ||
| JP2022538215A5 (enExample) | ||
| WO2008122793A3 (en) | Blood group antibody screening | |
| JP2007517227A5 (enExample) | ||
| JP2010505386A5 (enExample) | ||
| WO2009114869A3 (en) | Methods of preparation and composition of peptide constructs useful for treatment of rheumatoid arthritis |